A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.

Maloney, David G; Ogura, Michinori; Fukuhara, Noriko; Davis, Jaclyn; Lasher, Janet; Izquierdo, Miguel; Banerjee, Hiya; Tobinai, Kensei

Maloney, David G; Ogura, Michinori; Fukuhara, Noriko; Davis, Jaclyn; Lasher, Janet; Izquierdo, Miguel; Banerjee, Hiya; Tobinai, Kensei.

Afiliación

Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Ogura M; Department of Hematology/Oncology, Kasugai Municipal Hospital, Aichi, Japan.
Fukuhara N; Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan.
Davis J; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
Lasher J; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
Izquierdo M; Novartis Pharma AG, Basel, Switzerland; and.
Banerjee H; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
Tobinai K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Blood Adv ; 4(16): 3886-3893, 2020 08 25.

Article en En | MEDLINE | ID: mdl-32810220

Asunto(s)

Linfoma de Células B; Recurrencia Local de Neoplasia; Anticuerpos Monoclonales Humanizados; Humanos; Rituximab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Blood Adv Año: 2020 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google